Literature DB >> 23140287

Ascorbic acid in cancer chemoprevention: translational perspectives and efficacy.

Mohammad F Ullah1, Showket H Bhat, Eram Hussain, Faisel Abu-Duhier, Aamir Ahmad, S M Hadi.   

Abstract

Chemoprevention, which is referred to as the use of nontoxic natural or synthetic chemicals to intervene in multistage carcinogenesis has since decades attracted a considerable interest in plant-derived chemical constituents often termed as "phytochemicals" or sometimes as "Nutraceuticals" in case they are derived from dietary sources. A comprehensive search of the literature show that such an interest in natural product pharmacology has surged in the last 25 years and particularly risen at exponential rates since the last one decade. Phytochemicals such as curcumin (from spice turmeric), resveratrol (from red wine) and genistein (from soy) share the major efforts as indicated by overwhelming publications, despite skepticism concerning their bioavailability. Ascorbic acid (AA), the popular anti-oxidant in fruits and vegetables, has even a longer historical perspective than these dietary agents as for more than 35 years; there had been lingering questions about the efficacy of AA in cancer therapy. The footprints of AA from "scurvy" to "cancer" though complex seems to carry potential provided the puzzle could be set right. The use of AA in cancer treatment has been debated extensively as evident from the literature but surprisingly the complementing early phase bench work on the mechanistic studies for anticancer action was rather retarded. Proposed mechanisms of action for AA in the prevention and treatment of cancer includes antioxidant as well as pro-oxidant properties, stimulation of the immune system, altering carcinogen metabolism, enhancement of collagen synthesis necessary for tumor encapsulation and interference with cancer cell signaling. The observation that the intravenous administration of AA enhances its bioavailability to the extent of deriving pharmacological benefits against cancer has in recent years partially supported the clinical plausibility (efficacy) of AA towards realizing its translational advantage. Here, we provide an overview of AA with regard to its potential in the management of cancer disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23140287     DOI: 10.2174/138945012804545669

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  5 in total

Review 1.  Targeting cancer vulnerabilities with high-dose vitamin C.

Authors:  Bryan Ngo; Justin M Van Riper; Lewis C Cantley; Jihye Yun
Journal:  Nat Rev Cancer       Date:  2019-05       Impact factor: 60.716

Review 2.  Dietary intake and ovarian cancer risk: a systematic review.

Authors:  Tracy E Crane; Beman R Khulpateea; David S Alberts; Karen Basen-Engquist; Cynthia A Thomson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-10-18       Impact factor: 4.254

Review 3.  Understanding the Prooxidant Action of Plant Polyphenols in the Cellular Microenvironment of Malignant Cells: Role of Copper and Therapeutic Implications.

Authors:  Mohd Farhan; Asim Rizvi
Journal:  Front Pharmacol       Date:  2022-06-20       Impact factor: 5.988

4.  Hormetic dose response to L-ascorbic acid as an anti-cancer drug in colorectal cancer cell lines according to SVCT-2 expression.

Authors:  Sungrae Cho; Jin Sung Chae; Hocheol Shin; Yujeong Shin; Haeun Song; Youngwook Kim; Byong Chul Yoo; Kangsan Roh; Seungchan Cho; Eui-Joon Kil; Hee-Seong Byun; Sang-Ho Cho; Seyeon Park; Sukchan Lee; Chang-Hwan Yeom
Journal:  Sci Rep       Date:  2018-07-27       Impact factor: 4.379

5.  Clinical experience with intravenous administration of ascorbic acid: achievable levels in blood for different states of inflammation and disease in cancer patients.

Authors:  Nina Mikirova; Joseph Casciari; Neil Riordan; Ronald Hunninghake
Journal:  J Transl Med       Date:  2013-08-15       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.